{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:56:40Z","timestamp":1777420600845,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T00:00:00Z","timestamp":1383696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    On June 8, 2011, the United States Food and Drug Administration (FDA) reported safety concerns regarding statin-related myopathies and advised further restrictions on simvastatin dosing. These restrictions reduced the maximum dose for specific patient characteristics, primarily certain concomitant medications.\n                    <jats:bold>Objective:<\/jats:bold>\n                    The purpose of this study was to compare the effectiveness of 2 different pharmacist-conducted educational interventions on appropriate simvastatin use in the primary care setting.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This retrospective cohort analysis was conducted in 2 academic medical center clinics. Patients prescribed simvastatin before June 8, 2011, requiring dosage adjustment based on labeling changes were evaluated for study inclusion. The pharmacists\u2019 interventions included: 30-minute didactic session for prescribers or patient-specific recommendation communicated with the physician during the patient\u2019s follow-up visit. Primary outcomes were the number of patients prescribed FDA-recommended simvastatin doses after pharmacist intervention and the intervention\u2019s impact on low-density lipoprotein (LDL).\n                    <jats:bold>Results:<\/jats:bold>\n                    Medical record review identified 1173 patients prescribed simvastatin prior to June 8, 2011; 126 patients qualified for study inclusion. After controlling for baseline characteristics, the likelihood of patients being prescribed an appropriate dose postintervention increased if they were in the patient-specific recommendation group (odds ratio [OR] = 10.59; 95% CI = 3.43-32.69;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .0001). LDL change occurred at a similar rate between intervention groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .652).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Following FDA labeling changes for simvastatin, patient-specific recommendations made by pharmacists correlated with a greater likelihood of appropriate simvastatin dosing compared with a one-time didactic education session. Patient-specific recommendations positively affect prescribing habits and making steps to improve patient safety.\n                  <\/jats:p>","DOI":"10.1177\/1060028013511323","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T15:04:57Z","timestamp":1390316697000},"page":"54-61","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Pharmacists\u2019 Interventions and Simvastatin Dose Restrictions"],"prefix":"10.1177","volume":"48","author":[{"given":"Bethany R.","family":"Shoulders","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea S.","family":"Franks","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN, USA"},{"name":"University of Tennessee Graduate School of Medicine, Knoxville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick B.","family":"Barlow","sequence":"additional","affiliation":[{"name":"University of Tennessee Graduate School of Medicine, Knoxville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli D.","family":"Williams","sequence":"additional","affiliation":[{"name":"University of Tennessee Graduate School of Medicine, Knoxville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle Z.","family":"Farland","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,11,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02030-2"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.07.001."},{"key":"e_1_3_2_5_2","unstructured":"Stagnitti MN. Trends in statin utilization and expenditures for the U.S. civilian noninstitutionalized population 2000 and 2005. http:\/\/meps.ahrq.gov\/mepsweb\/data_files\/publications\/st205\/stat205.pdf. Accessed September 6 2013."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100098"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.t01-1-00625.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.04.017"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004273992"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90151-5"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104609"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP48497"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.108507"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.21.2585"},{"key":"e_1_3_2_15_2","unstructured":"US Food and Drug Administration. FDA drug safety communication: ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm204882.htm. Accessed March 26 2013."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.06.034"},{"key":"e_1_3_2_17_2","unstructured":"US Food and Drug Administration. FDA drug safety communication: new restrictions contraindications and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm256581.htm#Simvastatin_Dose_Limitations. Accessed March 26 2013."},{"key":"e_1_3_2_18_2","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: revised dose limitation for Zocor (simvastatin) when taken with amiodarone. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm283137.htm#.T7BrDYvVnfc.email. Accessed March 26 2013."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.5.553"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2003.9.3.269"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K618"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G300"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G300"},{"key":"e_1_3_2_24_2","first-page":"e103","article-title":"Strategic opportunities for effective optimal prescribing and medication management","volume":"16","author":"Sketris IS","year":"2009","unstructured":"Sketris IS, Langille Ingram EM, Lummis HL. Strategic opportunities for effective optimal prescribing and medication management. Can J Clin Pharmacol. 2009;16:e103-e125.","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta8060"},{"key":"e_1_3_2_26_2","first-page":"162","article-title":"Impact of an educational intervention on steroid prescribing and dosing effect on patient outcomes in COPD exacerbations","volume":"8","author":"Hope NH","year":"2010","unstructured":"Hope NH, Ray SM, Franks AS, Heidel E. Impact of an educational intervention on steroid prescribing and dosing effect on patient outcomes in COPD exacerbations. Pharm Pract. 2010;8;162-166.","journal-title":"Pharm Pract"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013511323","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028013511323","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013511323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:39Z","timestamp":1777374879000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028013511323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,6]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1177\/1060028013511323"],"URL":"https:\/\/doi.org\/10.1177\/1060028013511323","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,6]]}}}